학술논문
RETFusion Testing in Patients With NSCLC: The RETING Study
Document Type
Article
Author
Conde, Esther; Hernandez, Susana; Rodriguez Carrillo, Jose Luis; Martinez, Rebeca; Alonso, Marta; Curto, Daniel; Jimenez, Beatriz; Caminoa, Alejandra; Benito, Amparo; Garrido, Pilar; Clave, Sergi; Arriola, Edurne; Esteban-Rodriguez, Isabel; De Castro, Javier; Sansano, Irene; Felip, Enriqueta; Rojo, Federico; Dómine, Manuel; Abdulkader, Ihab; Garcia-Gonzalez, Jorge; Teixido, Cristina; Reguart, Noemi; Compañ, Desamparados; Insa, Amelia; Mancheño, Nuria; Palanca, Sarai; Juan-Vidal, Oscar; Baixeras, Nuria; Nadal, Ernest; Cebollero, Maria; Calles, Antonio; Martin, Paloma; Salas, Clara; Provencio, Mariano; Aranda, Ignacio; Massuti, Bartomeu; Lopez-Vilaro, Laura; Majem, Margarita; Paz-Ares, Luis; Lopez-Rios, Fernando
Source
JTO Clinical and Research Reports; April 2024, Vol. 5 Issue: 4
Subject
Language
ISSN
26663643
Abstract
RETinhibitors with impressive overall response rates are now available for patients with NSCLC, yet the identification of RETfusions remains a difficult challenge. Most guidelines encourage the upfront use of next-generation sequencing (NGS), or alternatively, fluorescence in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) when NGS is not possible or available. Taken together, the suboptimal performance of single-analyte assays to detect RETfusions, although consistent with the notion of encouraging universal NGS, is currently widening some of the clinical practice gaps in the implementation of predictive biomarkers in patients with advanced NSCLC.